HT-0712

From Wikipedia, the free encyclopedia

Other namesHT-0712, IPL 455,903
ATC code
  • None
CAS Number
PubChem CID
HT-0712
Clinical data
Other namesHT-0712, IPL 455,903
ATC code
  • None
Identifiers
  • (3S,5S)-5-(3-(Cyclopentyloxy)-4-methoxyphenyl)-3-(3-methylbenzyl)piperidin-2-one
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC25H31NO3
Molar mass393.527 g·mol−1
3D model (JSmol)
  • O=C3NC[C@H](c2cc(OC1CCCC1)c(OC)cc2)C[C@H]3Cc4cccc(c4)C
  • InChI=1S/C25H31NO3/c1-17-6-5-7-18(12-17)13-20-14-21(16-26-25(20)27)19-10-11-23(28-2)24(15-19)29-22-8-3-4-9-22/h5-7,10-12,15,20-22H,3-4,8-9,13-14,16H2,1-2H3,(H,26,27)/t20-,21-/m1/s1 checkY
  • Key:ABEJDMOBAFLQNJ-NHCUHLMSSA-N checkY
  (verify)

HT-0712, also known as IPL-455903,[1] is an experimental cognitive enhancing drug (nootropic) which is currently undergoing clinical trials. It is currently being licensed by Helicon Therapeutics in San Diego, California. It was originally discovered and tested as part of a preclinical anti-inflammatory program by Inflazyme Pharmaceuticals.[2]

HT-0712 appears to act as a PDE4 inhibitor, thereby increasing cAMP levels. When cAMP levels are increased in neurons, this may trigger the activation of cAMP response element-binding proteins (CREB). CREBs are transcription factors involved in the formation of long-term memory.[2]

The side effects of the drug are not yet fully known.

Research

References

External links

Related Articles

Wikiwand AI